193 related articles for article (PubMed ID: 24918799)
1. A short-acting GLP-1 analog or prandial insulin to supplement basal insulin?--Moving toward personalized management of type 2 diabetes mellitus.
Hirsch IB; Schneider D; King A; Polonsky WH; Reid TS; Shubrook J; Verderese CA; Wallace J; Riddle MC
Postgrad Med; 2014 May; 126(3):135-44. PubMed ID: 24918799
[TBL] [Abstract][Full Text] [Related]
2. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.
Goldenberg RM; Berard L
Curr Med Res Opin; 2018 Jan; 34(1):1-10. PubMed ID: 28836861
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
Owens DR; Monnier L; Bolli GB
Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option.
Gómez-Huelgas R; Azriel S; Puig-Domingo M; Vidal J; de Pablos-Velasco P
Int J Clin Pharmacol Ther; 2015 Mar; 53(3):230-40. PubMed ID: 25066229
[TBL] [Abstract][Full Text] [Related]
5. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
Banerji MA; Baron MA; Gao L; Blonde L
Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
[TBL] [Abstract][Full Text] [Related]
6. Treating patients with diabetes of long duration: GLP-1 receptor agonists and insulin in combination.
Moghissi ES
J Am Osteopath Assoc; 2014 May; 114(5 Suppl 2):S22-9. PubMed ID: 24769505
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 analog and insulin combination therapy in the management of adults with type 2 diabetes mellitus.
Tzefos M; Olin JL
Ann Pharmacother; 2010; 44(7-8):1294-300. PubMed ID: 20530705
[TBL] [Abstract][Full Text] [Related]
8. The importance of postprandial glycemic control: optimizing add-on therapy to basal insulin.
Shaefer CF; Anderson J
Postgrad Med; 2016 Jan; 128(1):137-44. PubMed ID: 26548422
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of prandial and non-prandial GLP-1 receptor agonists in type 2 diabetes therapy.
Davidson JA
Postgrad Med; 2015; 127(8):827-41. PubMed ID: 26428031
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.
Huthmacher JA; Meier JJ; Nauck MA
Diabetes Care; 2020 Sep; 43(9):2303-2312. PubMed ID: 32910778
[TBL] [Abstract][Full Text] [Related]
11. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
12. Advances in Type 2 Diabetes: Focus on Basal Insulin/Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy.
Shubrook JH
J Fam Pract; 2018 Aug; 67(8 suppl):S49-S54. PubMed ID: 30137054
[No Abstract] [Full Text] [Related]
13. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Rosenstock J; Fonseca VA; Gross JL; Ratner RE; Ahrén B; Chow FC; Yang F; Miller D; Johnson SL; Stewart MW; Leiter LA;
Diabetes Care; 2014 Aug; 37(8):2317-25. PubMed ID: 24898300
[TBL] [Abstract][Full Text] [Related]
14. [When injectable diabetes therapy becomes necessary. Insulin or GLP-1 analogs?].
Stiefelhagen P
MMW Fortschr Med; 2011 Jan; 153(1-2):14. PubMed ID: 24761480
[No Abstract] [Full Text] [Related]
15. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations.
Carris NW; Taylor JR; Gums JG
Drugs; 2014 Dec; 74(18):2141-52. PubMed ID: 25414121
[TBL] [Abstract][Full Text] [Related]
16. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy.
Hirsch IB; Buse JB; Leahy J; McGill JB; Peters A; Rodbard HW; Rubin RR; Skyler JS; Verderese CA; Riddle MC
Diabetes Obes Metab; 2014 Mar; 16(3):206-14. PubMed ID: 23711193
[TBL] [Abstract][Full Text] [Related]
17. Lixisenatide, a novel GLP-1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus.
Bolli GB; Owens DR
Diabetes Obes Metab; 2014 Jul; 16(7):588-601. PubMed ID: 24373190
[TBL] [Abstract][Full Text] [Related]
18. User's guide to mechanism of action and clinical use of GLP-1 receptor agonists.
Shaefer CF; Kushner P; Aguilar R
Postgrad Med; 2015; 127(8):818-26. PubMed ID: 26371721
[TBL] [Abstract][Full Text] [Related]
19. Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
Trautmann ME; Vora J
Diabet Med; 2018 Jun; 35(6):694-706. PubMed ID: 29478255
[TBL] [Abstract][Full Text] [Related]
20. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.
Trujillo JM; Nuffer W
Pharmacotherapy; 2014 Nov; 34(11):1174-86. PubMed ID: 25382096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
